Deal to focus on Xpovio, a multiple myeloma treatment, in mainland China.
Antengene and Hansoh Pharmaceutical Group Company Limited announced an agreement to collaborate on the commercialization of Xpovio, a treatment for multiple myeloma, in mainland China. According to the agreement, Antengene will continue to focus on research and development, regulatory approvals and affairs, product supply, and distribution, with Hansoh focusing solely on commercialization efforts.
Antengene will receive approximately $27.5 million in upfront payments, with $13 million upon the initial signing. Antengene will continue to record revenues from sales of Xpovio in the mainland of China and Hansoh Pharma will charge a service fee to Antengene, according to a company press release.
"Hansoh Pharma is excited to enter into this partnership with Antengene and is committed to bringing XPOVIO® to more patients in China," said Yuan Sun, executive director, Hansoh Pharma, in the company release. "We believe that Xpovio is a drug with great commercial potential, addressing huge unmet medical needs for those hematologic patients in China. In addition to obtaining approvals in multiple countries and regions globally for multiple myeloma and diffuse large B-cell lymphoma, Xpovio has indication expansion potential in myelofibrosis, endometrial cancer, as well as T/NK-cell lymphoma. We look forward to collaborating with Antengene and make Xpovio available to the widest possible number of Chinese patients with hematological malignancies."
Reference: Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China. PR Newswire. August 10, 2023. Accessed August 14, 2023. https://www.prnewswire.com/news-releases/antengene-enters-into-commercialization-partnership-with-hansoh-pharma-for-firstonly-in-class-xpo1-inhibitor-xpovioselinexor-in-the-mainland-of-china-301898339.html